PETIT ROBERT 4

What Happened
Robert Petit, Chief Medical Officer and Chief Scientific Officer of OS Therapies Inc. (OSTX), was granted options to purchase 100,000 shares on January 22, 2026. The Form 4 reports the award as a derivative acquisition with an acquisition value of $0.00 (the grant itself required no cash payment). The options vest in full on the one‑year anniversary of the grant date, provided Petit remains an employee on that date. This was a grant/award (not a sale or open‑market purchase) and does not represent immediate buying or selling of shares.

Key Details

• Transaction date: January 22, 2026; Form 4 filed February 13, 2026 (filed late relative to the typical 2‑business‑day Form 4 rule).
• Transaction type: Grant/award of stock options (derivative); table shows acquisition at $0.00.
• Quantity: Options to purchase 100,000 shares.
• Vesting: Options vest in full one year after grant if still employed (per footnote).
• Shares owned after transaction: Not specified in the provided excerpt.
• Remarks: Robert Petit serves as CMO and CSO of OS Therapies.
• Footnote: The grant is governed by a stock option award agreement; the Form 4 does not detail exercise price or other economic terms beyond the vesting condition.

Context

• This is an equity compensation grant, not an exercised option or open‑market buy — no immediate proceeds or sales. Such grants are common for executive compensation and do not by themselves indicate the insider is buying or selling shares in the market.
• Because the filing was submitted on Feb 13 for a Jan 22 grant, the report appears late relative to standard Form 4 timing requirements; late filings can result from administrative delays but are worth noting for transparency.